Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, Rasche L. Da Vià MC, et al. Among authors: topp ms. Nat Med. 2021 Apr;27(4):616-619. doi: 10.1038/s41591-021-01245-5. Epub 2021 Feb 22. Nat Med. 2021. PMID: 33619368 Clinical Trial.
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H. Topp MS, et al. J Clin Oncol. 2020 Mar 10;38(8):775-783. doi: 10.1200/JCO.19.02657. Epub 2020 Jan 2. J Clin Oncol. 2020. PMID: 31895611 Clinical Trial.
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Steinhardt MJ, Krummenast FC, Rosenwald A, Gerhard-Hartmann E, Heidemeier A, Einsele H, Topp MS, Duell J. Steinhardt MJ, et al. Among authors: topp ms. J Cancer Res Clin Oncol. 2022 Jan;148(1):205-214. doi: 10.1007/s00432-021-03663-x. Epub 2021 Jun 3. J Cancer Res Clin Oncol. 2022. PMID: 34085097 Free PMC article.
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM.
Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, Riedel A, Hüper S, Peter J, Walter W, Haertle L, Meggendorfer M, Topp MS, Rosenwald A, Da Via MC, Bolli N, Weinhold N, Einsele H, Haferlach C, Kortüm KM, Rasche L. Truger MS, et al. Among authors: topp ms. Blood Adv. 2021 Oct 12;5(19):3794-3798. doi: 10.1182/bloodadvances.2021004418. Blood Adv. 2021. PMID: 34471932 Free PMC article.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Bannerji R, et al. Among authors: topp ms. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. Lancet Haematol. 2022. PMID: 35366963 Free PMC article. Clinical Trial.
Effect of serum and CTL on focal growth of human cytomegalovirus.
Sinzger C, Mangin M, Weinstock C, Topp MS, Hebart H, Einsele H, Jahn G. Sinzger C, et al. Among authors: topp ms. J Clin Virol. 2007 Feb;38(2):112-9. doi: 10.1016/j.jcv.2006.11.009. Epub 2007 Jan 3. J Clin Virol. 2007. PMID: 17204454
129 results